Drug insight: thalidomide as a treatment for multiple myeloma (Q36304004)

13 August 2017

1 reference

title

Drug insight: thalidomide as a treatment for multiple myeloma (English)

1 reference

13 August 2017

0 references

2

Kenneth C Anderson

1 reference

13 August 2017

1

Shaji Kumar

1 reference

13 August 2017

publication date

1 May 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

262-270

1 reference

Moving disease biology from the lab to the clinic

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Pathogenesis of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Bradycardia during therapy for multiple myeloma with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Low-dose thalidomide in myeloma: efficacy and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Thalidomide as initial therapy for early-stage myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Autologous peripheral blood progenitor cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Duration of immunosuppressive treatment for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0174

7 January 2021

Identifiers

DOI

10.1038/NCPONC0174

1 reference

Dimensions Publication ID

13 August 2017

1003343874

0 references

1 reference